VTVT: the cash flow

MyFinsight

For the year ending 2025-12-31, VTVT had $52,186K increase in cash & cash equivalents over the period.

Cash Flow	2025-12-31
Net loss before noncontrolling interest	-31,080
Depreciation expense	16
Loss on disposal of property and equipment	-6
Loss from g42 promissory note early redemption	0
Non-cash interest income	0
Share-based compensation expense	3,775
Realized gain on sale of investment in reneo pharmaceuticals, inc	0
Impairment of investments in anteris bio, inc	0
Change in fair value of warrants-Related Party	27
Change in fair value of warrants-Nonrelated Party	109
Prepaid expenses	-449
Other current assets	43
Other assets	-125
Accounts payable and accrued expenses	1,530
Contract liabilities	0
Other liabilities	-169
Net cash used in operating activities	-25,255
Proceed from sale of investments in reneo pharmaceuticals, inc	0
Net cash provided by (used in) investing activities	0
Proceeds from sale of class a common stock, pre-funded and common warrants, net of offering costs	77,476
Proceeds from sale of class a common stock and pre-funded warrants, net of offering costs	0
Proceeds from issuance of class a common stock, net of offering costs	0
Proceeds from sale of class a common stock to collaboration partner, net of offering costs	0
Proceeds from the exercise of stock options	16
Taxes paid related to net share settlement of equity awards	51
Proceeds from debt issuance	392
Repayment of notes payable	392
Net cash provided by financing activities	77,441
Net increase (decrease) in cash, cash equivalents	52,186
Total cash and cash equivalents, beginning of year	36,746
Total cash and cash equivalents, end of year	88,932

Unit: Thousand (K) dollars (except for numbers of shares and EPS).